Article info
PDFClinical and epidemiological research
Extended report
Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study
- Correspondence to Yukitomo Urata, Department of Rheumatology, Seihoku Chuo Hospital, 41 Nunoyacho, Gosyogawara 037-0053, Japan; yurata{at}dream.com
Citation
Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study
Publication history
- Received July 25, 2011
- Accepted July 25, 2011
- First published October 21, 2011.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions